Regulus Therapeutics Earnings miss, Revenue Inline In Q3

  • Investing.com
Regulus Therapeutics Earnings miss, Revenue Inline In Q3

Investing.com - Regulus Therapeutics reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.

Regulus Therapeutics announced earnings per share of $-0.5000 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.4950 on revenue of $0.00.

Regulus Therapeutics shares are down 53.92% from the beginning of the year and are trading at $1.6250 , down-from-52-week-high.

Regulus Therapeutics follows other major Healthcare sector earnings this month

Regulus Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.

J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100